Enhanced sustained release of furosemide in long circulating chitosan-conjugated PLGA nanoparticles

Abstract

Furosemide (FSM) is commonly used in the treatment of edema associated with congestive cardiac failure, cirrhosis of the liver, renal disease, including the nephrotic syndrome and hypertension. However, in ascites, it is clinically limited due to its frequent dosing and short biological half-life and its prolonged-release preparations are not available. Therefore, the main objective behind the present research work is to develop chitosan coated and conjugated poly (lactic-co-glycolic acid) (PLGA) nanocarriers, to sustain the delivery of FSM with improved systemic circulation. Emulsion-solvent evaporation technique was used for the preparation of nanoparticles. In-vivo pharmacokinetic study showed 2.6, 3.10, and 4.30 folds enhancement in relative availability of FSM for FSM-PLGA, FSM-chitosan-coated-PLGA and FSM-chitosan-conjugated- PLGA nanoparticles, respectively than FSM. The present research work concluded that FSM loaded chitosan conjugated PLGA nanoparticles could enhance the systemic circulation of FSM with improved pharmacokinetics parameters.

Platensimycin-Encapsulated Poly(lactic-co-glycolic acid) and Poly(amidoamine) Dendrimers Nanoparticles with Enhanced Anti-Staphylococcal Activity in Vivo

“…These results are consistent with our previous pharmacokinetic study of PTM in mice that PTM has a rapid clearance from the circulation system . Encouragingly, the encapsulation of PTM in either PLGA or PAMAM significantly improved its pharmacokinetic properties, consistent with those reports that NPs would significantly change the retention and biodistribution in humans and model animals. ,,− …”

<p>Nanoparticle Drug Delivery Systems for α-Mangostin</p>

“…Currently, nanotechnology can be applied for drug delivery systems, such drug controlled release, 95 delayed release and sustained release. 96 These nanoparticle formulations are the most commonly used in drug delivery systems. 97 Our objective review highlighted that the nanoparticle technology in nanomedicine applications is divided into three general classifications: increased water solubility, controlled release and targeted drug delivery.…”

Engineering of stealth (maghemite/PLGA)/chitosan (core/shell)/shell nanocomposites with potential applications for combined MRI and hyperthermia against cancer

“…55 Surface modification of PLGA NPs with a CS shell is possible thanks to attractive electrostatic interactions between the negatively charged PLGA particles and the positively charged CS. 56,57 Additional benefits of that CS functionalization are the optimization of the sustained drug release capabilities [58][59][60] and the enhancement of the uptake by targeted cells. [61][62][63][64] Therefore, CS surface coating onto these drug-and gene-loaded PLGA nanosystems may help in improving their biodistribution and therapeutic effects.…”